Apyx Medical Q2 Gaap EPS $(0.19) Beats $(0.20) Estimate, Sales $12.15M Beat $11.75M Estimate
Portfolio Pulse from saritha@benzinga.com
Apyx Medical (NASDAQ:APYX) reported Q2 GAAP EPS of $(0.19), beating the $(0.20) estimate, and sales of $12.15M, beating the $11.75M estimate. Despite beating estimates, both EPS and sales decreased compared to the same period last year.
August 08, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apyx Medical reported Q2 GAAP EPS of $(0.19), beating the $(0.20) estimate, and sales of $12.15M, beating the $11.75M estimate. However, both EPS and sales decreased compared to the same period last year.
While Apyx Medical beat both EPS and sales estimates, the year-over-year decrease in both metrics may temper investor enthusiasm. The mixed results could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100